IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Breast Cancer Etiopathogenesis Through Different Molecular Signatures (Biomarkers) Serving as a Chemical Mediators/Modulators (Pharmaco-Therapeutics): Gemcitabine Nanoparticles and Cisplatin Nanoliposome of Pharmaceutical Drug Delivery Targeting

Breast Cancer Etiopathogenesis Through Different Molecular Signatures (Biomarkers) Serving as a Chemical Mediators/Modulators (Pharmaco-Therapeutics): Gemcitabine Nanoparticles and Cisplatin Nanoliposome of Pharmaceutical Drug Delivery Targeting
View Sample PDF
Author(s): Zuber Peermohammed Shaikh (University of Pune, India)
Copyright: 2025
Pages: 22
Source title: Cancer Diagnosis, Treatment and Care: Reflections for the Education of Survivors and Healthcare Providers
Source Author(s)/Editor(s): Karis L. Clarke (Touro University California, USA)and Noran L. Moffett (Fayetteville State University, USA)
DOI: 10.4018/979-8-3693-5400-1.ch018

Purchase


Abstract

Chemotherapy is still mainstay treatment for various cancers. However, it has run into problems like low tumor selectivity and MDR (multidrug resistance). One creative solution to these problems is the use of nanotechnology materials for targeted drug delivery. This study's goals included improving cisplatin nanoliposomes and Gemcitabine Nanoparticles(NPs) and determining how toxic they were to breast cancer cell lines. The results of the study showed that cisplatin's and Gemcitabine NPs cytotoxic effects were increased in liposomes/NPs as opposed to in its free form. In conclusion, nanoliposome and Nanoparticle synthesis methods have proven to be an invaluable asset in improving therapeutic drugs, particularly in the area of chemotherapy. Nevertheless, it is essential to carefully assess the toxicity and fate of nanoliposomes before using them for pharmaceutical applications. These research aims to provide the numerous studies that have investigated the Anticancer effects of different medications formulated in nanoliposomes/NPs in various cell lines.

Related Content

Yiannis Koumpouros. © 2026. 36 pages.
Antonios Archontis, Yiannis Koumpouros. © 2026. 48 pages.
R Velmurugan, J Sudarvel, Ravi Thirumalaisamy. © 2026. 24 pages.
S. Ida Evangeline. © 2026. 20 pages.
Ramya Raghavan, Srusti Shankar Moger, SaiMahima Umesh, G N Bhuvana. © 2026. 36 pages.
Tiago Manuel Horta Reis da Silva. © 2026. 32 pages.
Tiago Manuel Horta Reis da Silva. © 2026. 32 pages.
Body Bottom